Contract Development Services

Drug development contract services company PPD announces initial public offering.

The acquisition expands Charles River’s scientific capabilities in cell therapy development.

Cambrex reports that the acquisition by the investment group will facilitate ongoing growth.

The companies announced a commercial supply agreement following FDA’s accelerated approval.

New training facilities, laboratories, packaging, gene therapy manufacturing, and biologics manufacturing highlight Thermo Fisher Scientific expansions.

Lubrizol Life Science Health adopts new name and opens commercial manufacturing facility.

Lonza, through its Ibex Solutions, will now cover preclinical and clinical development and manufacturing for a significant portion of Genmab’s pipeline.

Limited guidance and numerous challenges create confusion about the scope and timing of stability testing for drugs in development.

An understanding-during early development-of the solid form landscape of an API can enhance product quality and manufacturing processes.

New therapies, new technologies, global supply chain challenges, and political pressures draw pharma professionals to major industry event.

Bora Pharmaceuticals has announced it has achieved success in the latest FDA general inspection of its Zhunan facility with zero 483 observations.

CMOs and CDMOs expanded their services and facilities in the summer of 2019.

To help customers succeed, CDMOs have moved away from the ‘fee-for-service’ model to offer flexible, full-service partnerships.

Complex and potent molecules demand greater technical and regulatory expertise to ensure safe handling.

An agreement with Sanofi gives Catalent access to commercial spray drying facility in Haverhill, UK.

The company has expanded its high-potency API capability at its Riverview, MI, facility to serve the growing antibody drug conjugates market.

Two additional production lines expand Lonza’s HPAPI capacity at Visp, Switzerland facility.

Tergus Pharma announced a partnership with Great Point Partners and construction of a new commercial manufacturing facility in North Carolina.

Expanded controlled substance capabilities enables Particle Sciences to develop and manufacture Schedule I–V drugs.

The company announced plans to construct a 1.3 million-ft2 integrated manufacturing center in Chengdu, China.

Recipharm Inhalation Solutions is an integrated service for inhalation products.

Samsung BioLogics will provide contract development organization services to drug developer GI Innovation.

Lonza’s SimpliFiH Services addresses bioavailability challenges with drug substance, solid-state characterization, and drug product for first-in-human studies.

Expansion at the Eberbach, Germany facility includes two Vegicap encapsulation lines, printing, inspection, and packaging capabilities.

The expansion of the CDMO’s Skokie, IL facility includes additional refrigeration and freezer space.

The companies will merge to offer a broader range of analytical data packages and regulatory support for biopharmaceuticals.

Catalent’s acquisition of Paragon Bioservices will provide expertise and in expanding gene and cell therapy markets.

The new service offers a flexible, customizable suite of products and services designed to accelerate the clinical and commercial development of gene and cell therapies.

The acquisition of CiVentiChem’s facility in the United States is expected to enhance UK-based Sterling Pharma Solutions’ chemistry development capabilities.

Catalent invests $5 million in hot melt extrusion capabilities at Somerset, NJ facility.